Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

Tolvaptan phosphate

From Wikipedia, the free encyclopedia
Drug for cardiac edema
Pharmaceutical compound
Tolvaptan phosphate
Clinical data
Trade namesSamtasu
Other namesTolvaptan sodium phosphate; OPC-61815
Identifiers
  • [(5R)-7-Chloro-1-[2-methyl-4-[(2-methylbenzoyl)amino]benzoyl]-2,3,4,5-tetrahydro-1-benzazepin-5-yl] dihydrogen phosphate
CAS Number
PubChemCID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC26H26ClN2O6P
Molar mass528.93 g·mol−1
3D model (JSmol)
  • CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)OP(=O)(O)O)C
  • InChI=InChI=1S/C26H26ClN2O6P/c1-16-6-3-4-7-20(16)25(30)28-19-10-11-21(17(2)14-19)26(31)29-13-5-8-24(35-36(32,33)34)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24H,5,8,13H2,1-2H3,(H,28,30)(H2,32,33,34)/t24-/m1/s1
  • Key:XTCFGVRVASPRTK-XMMPIXPASA-N

Tolvaptan phosphate is a drug used for the treatment ofcardiac edema. It is aprodrug oftolvaptan,[1][2] formulated as the salt tolvaptan sodium phosphate, forintravenous administration. Tolvaptan phosphate is converted into the active drug tolvaptan in the human body following administration.

It wasdeveloped byOtsuka Pharmaceutical Co. and was approved for use in Japan in 2022.[3]

References

[edit]
  1. ^Kinugawa K, Nakata E, Hirano T, Kim S (March 2022)."Tolerability of the Intravenously Administered Tolvaptan Prodrug, OPC-61815, in Patients With Congestive Heart Failure Who Have Difficulty With, or Are Incapable of, Oral Intake (TRITON-HF) - A Phase III, Multicenter, Open-Label Trial".Circulation Journal.86 (7):1068–1078.doi:10.1253/circj.CJ-21-0926.PMID 35264514.S2CID 247362001.
  2. ^Sato N, Uno S, Yamasaki Y, Hirano T, Kim S, et al. (OPC-61815 Investigators) (March 2022)."Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of OPC-61815, a Prodrug of Tolvaptan for Intravenous Administration, in Patients With Congestive Heart Failure - A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Trial".Circulation Journal.86 (4):699–708.doi:10.1253/circj.CJ-21-0430.PMID 34511586.S2CID 237493273.
  3. ^"Otsuka Obtains Approval in Japan for SAMTASU® for I.V. Infusion, a V2 -Receptor Antagonist for the Treatment of Cardiac Edema" (Press release). Otsuka Pharmaceutical Co., Ltd. March 28, 2022.Archived from the original on November 13, 2022. RetrievedJune 11, 2022.
Stub icon

Thisdrug article relating to thecardiovascular system is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Tolvaptan_phosphate&oldid=1265626593"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2025 Movatter.jp